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Abstract
Background: GPR110 is an orphan G protein-coupled receptor–a receptor without a known ligand, a known
signaling pathway, or a known function. Despite the lack of information, one can assume that orphan receptors
have important biological roles. In a retroviral insertion mutagenesis screen in the mouse, we identified GPR110 as
an oncogene. This prompted us to study the potential isoforms that can be gleaned from known GPR110
transcripts, and the expression of these isoforms in normal and transformed human tissues.
Methods: Various epitope-tagged isoforms of GPR110 were expressed in cell lines and assayed by western blotting
to determine cleavage, surface localization, and secretion patterns. GPR110 transcript and protein levels were
measured in lung and prostate cancer cell lines and clinical samples, respectively, by quantitative PCR and
immunohistochemistry.
Results: We found four potential splice variants of GPR110. Of these variants, we confirmed three as being
expressed as proteins on the cell surface. Isoform 1 is the canonical form, with a molecular mass of about 100 kD.
Isoforms 2 and 3 are truncated products of isoform 1, and are 25 and 23 kD, respectively. These truncated isoforms
lack the seven-span transmembrane domain characteristic of GPR proteins and thus are not likely to be membrane
anchored; indeed, isoform 2 can be secreted. Compared with the median gene expression of ~200 selected genes,
GPR110 expression was low in most tissues. However, it had higher than average gene expression in normal
kidney tissue and in prostate tissues originating from older donors. Although identified as an oncogene in murine
T lymphomas, GPR110 is greatly overexpressed in human lung and prostate cancers. As detected by
immunohistochemistry, GPR110 was overexpressed in 20 of 27 (74%) lung adenocarcinoma tissue cores and in 17
of 29 (59%) prostate adenocarcinoma tissue cores. Additionally, staining with a GPR110 antibody enabled us to
differentiate between benign prostate hyperplasia and potential incipient malignancy.
Conclusion: Our work suggests a role for GPR110 in tumor physiology and supports it as a potential therapeutic
candidate and disease marker for both lung and prostate cancer.
Background
GPCRs are seven transmembrane receptors that vary
extensively in their biological functions. Upon ligand
b i n d i n g ,t h e s er e c e p t o r st r a n s d u c eas i g n a lv i aaGp r o -
tein. This fact has been used extensively in pharmacol-
ogy to select inhibitors of biological pathways. A large
fraction of all drugs currently on the market target
GPCRs. Drugs targeting members of this integral mem-
brane protein superfamily represent the core of modern
medicine [1].
There are many so-called orphan receptors–receptors
without a known ligand, a known signaling pathway, or
a known function. Despite the lack of information, one
can assume that orphan receptors have important biolo-
gical roles. One of these orphan receptors is GPR110,
about which little is known other than its gene structure
and potential isoforms that can be inferred from pub-
lished transcript data. In a large murine retroviral muta-
genesis screen, we identified GPR110 as an oncogene.
The GPR110 protein contains two protein domains
where cleavage can potentially occur: the SEA domain
and the GPS domain. Self-cleavage has been reported
for the SEA domain in human MUC1 [2] and in rat
Muc3 [3]. According to these reports, the cleaved SEA
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by noncovalent interactions. Cleavage at the GPS
domain was first demonstrated in the GPCR latrophilin
[4]. Cleaved products of an overexpressed GPCR might
be found in the blood, which could serve as an easily
accessible clinical marker. Furthermore, alternatively
spliced isoforms that are not membrane anchored may
instead be potentially secreted and also be found in the
blood. The rich possibility of GPR110 as a therapeutic
candidate and diagnostic marker led us to study the
s y n t h e s i so fi t sv a r i o u si s o f o r m sa n dt os u r v e yh u m a n
cancers for its overexpression.
Methods
Cloning and tagging of GPR110 isoforms
GPR110 isoforms 1 and 2 were amplified from PC-3
cDNA using a set of primers designed to their common
5’ UTR and their respective 3’ UTR regions. Forward
primer 5’-CACCAGTCACAGACTATGC-3’ and reverse
primer 5’-ACCCGATCGAATACTGAGC-3’ (isoform 1,
3’ UTR) and reverse primer 5’-CAGGGGAATCTCTT-
GAACCCG-3’ (isoform 2, 3’ UTR). Products from the
first PCR reactions were used as templates in a nested
PCR with the following primers: forward primer
5’-TTCGGTACCACCATGAAAGTTGGAGTGC-3’
(110_F_Kpn), reverse primer 5’-CCCTCTAGATTATT-
CATTTGAGACAAACTG-3’ (isoform 1, with stop
codon) and reverse primer 5’-CCTTCTAGA-
GATTGTGCCATTGCACTC-3’ (isoform 2, no stop
codon). The PCR products were then cloned into
pcDNA3.1(+) (Invitrogen) using KpnIa n dXbaIr e s t r i c -
tion sites to make constructs pcDNA/Iso1 and
pcDNA/Iso2. Sequences of these clones matched pub-
lished RefSeq sequences on NCBI. GPR110 isoform 3
with no stop codon was amplified from pcDNA/Iso1
using the primers 110_F_Kpn and reverse primer 5’-
CCCTCTAGACCGAAATTGGGTGACC-3’.Av e r s i o n
of isoform 1 with no stop codon was amplified from
the pcDNA/Iso1 construct using primer 110_F_Kpn
and reverse primer 5’-CCCTCTAGATTCATTTGA-
GACAAACTGAG-3’. Isoforms 1-3 containing no stop
codons were then cloned into a version of pcDNA3.1
(+) containing the HA epitope between restriction sites
XbaIa n dApaIon the pcDNA3.1(+) vector creating
constructs Iso1-HA, Iso2-HA, and Iso3-HA.
Three additional HA-tagged versions of isoform 1
were made using pcDNA/Iso1 as a template with the
QuikChangeII Site-Directed Mutagenesis Kit (Strata-
gene). The following primers were used for the
three constructs: HA466: 5’-TTAGAATTATCAGAG-
CAAAGTACCCATACGATGTTCCAGATTACGCTAC-
CACAGACTGCAACAG-3’ and 5’-
CTGTTGCAGTCTGTGGTAGCGTAATCTGGAA-
CATCGTATGGGTACTTTGCTCTGATAATTCTAA-
3’; HA1036: 5’-CCTGCAGCAGTGGCTACCCATAC-
GATGTTCCAGATTACGCTAGGGGAAACATCA-
CAGC-3’ and 5’-
GCTGTGATGTTTCCCCTAGCGTAATCTGGAA-
CATCGTATGGGTAGCCACTGCTGCAGG-3’;a n d
HA1393: 5’-GTCTTACTGCGGGAAGAAAAGTACC-
CATACGATGTTCCAGATTATGCCAGCTCACG-3’
and 5’-CGTGAGCTGGCATAATCTGGAACATCG-
TATGGGTACTTTTCTTCCCGCAGTAAGAC-3’.C o n -
struct HA466 has a HA tag located N-terminal to the
SEA domain whereas HA1036 and HA1393 contain tags
located between the SEA and GPS domains.
Transfections, immunoblotting, cell surface detection, and
immunoprecipitation
All cell lines were seeded in 6-well plates at a cell den-
s i t yo f4×1 0
5 cells per well. Each well was transfected
with 4 μgo fD N Aa n d1 0μl of Lipofectamine 2000
(Invitrogen) according to the manufacturer’si n s t r u c -
tions. Cells were incubated in lysis buffer (0.5% Triton
X-100, 50 mM Tris pH7.4, 5 mM EDTA, and 150 mM
NaCl). Cell lysates were run on 4-12% Bis-Tris gels in
NuPAGE MOPS buffer (Invitrogen) and transferred to
nitrocellulose membranes. Blots were blocked in 5%
nonfat dry milk (wt/vol) in TBST (20 mM Tris, 150
mM NaCl, 0.1% Tween-20) and followed by incubation
with primary antibody (anti-HA, HA.11 from Covance).
After washing with TBST, blots were incubated with an
anti-mouse Ig secondary antibody (Southern Biotech
#1010-04), and developed with 1 Step NBT/BCIP
(Pierce). For deglycosylation reactions, samples dena-
tured in protein loading buffer were treated with 500
units of PNGase F (NEB) in 1× G7 Reaction Buffer and
1% NP40 for 1.5 hours at 37°C.
For cell surface detection, two 10 cm dishes of
HEK293 were transfected with Lipofectamine 2000 for
each construct according to manufacturer’s instructions.
Approximately 24 hr post transfection, surface proteins
were isolated using the Cell Surface Protein Isolation Kit
(Pierce). Purification fractions were assayed by immuno-
blotting as described above using an anti-GAPDH anti-
body (Ambion), an anti-b1 integrin antibody (MAB2000,
Chemicon), and HA.11 (Covance).
Immunoprecipitation of media samples was done using
Protein-G agarose (Invitrogen). 200 μl of Protein-G agar-
ose (50% slurry) was washed in lysis buffer and incubated
with 5 μg of HA.11 antibody for 1 hr at 4°C. The conju-
gated beads were washed 3 times with lysis buffer to
remove any excess antibody. 15 μl aliquots of beads were
incubated with 1 mL of media from transfections of var-
ious GPR110 isoforms overn i g h ta t4 ° Cw i t hr o c k i n g .
Beads were washed in lysis buffer and then boiled for 10
min in SDS Loading Buffer. Samples were then assayed by
immunoblotting as described above.
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Cell lines HEK293T/17, HeLa, PC-3, LNCaP, DU145,
A549, NCI-H460, and NCI-H23 were obtained from the
American Type Culture Collection. With the exception
of LNCaP, all human cell lines used are part of the
NCI-60 panel of reference cell lines, for which extensive
expression analysis and significant chemical compound
screening assays have been done. In addition, these cell
lines have been used in xenograft cancer models. All
cultures were grown in media supplemented with 10%
fetal bovine serum (Hyclone), 100 U/mL penicillin, and
100 μg/mL streptomycin. HEK293T/17 cells were main-
tained in DMEM (Cellgro); PC-3 and A549 in F12K
(Hyclone) with 2 mM glutam i n e ;L N C a P ,N C I - H 4 6 0 ,
and NCI-H23 in RPMI with 2 mM glutamine (Hyclone)
and supplemented with 10 mM HEPES, 4.5 g/L glucose,
1 mM sodium pyruvate, and 1.5 g/L sodium bicarbo-
nate; DU145 and HeLa in MEM/EBSS (Hyclone) with 2
mM glutamine, 1 mM sodium pyruvate, 1.5 g/L sodium
bicarbonate, and 0.1 mM nonessential amino acids.
RNA and quantitative PCR
The FirstChoice Human Total RNA Survey Panel
(Ambion) was used to screen GPR110 expression in
normal human tissues. The Human Lung Cancer Tis-
sueScan Real Time Expression Panel (Origene) contain-
i n gc D N Af r o m4 0l u n gt u m o ra n d8n o r m a ll u n g
samples was used to screen GPR110 expression in lung
tumors. Additional human lung adenocarcinoma RNAs
were from Asterand, and normal lung RNAs from
Ambion and Biochain. RNA was extracted from frozen
mouse spleen and thymus tumor samples and from
human cell lines with the RNeasy Mini Kit (Qiagen).
Mouse RNA samples were treated with rDNase
(Ambion) prior to reverse transcription. For all cDNA
synthesis, 500 ng of RNA was reverse transcribed using
the SuperScript First-Strand Synthesis System III
(Invitrogen).
Quantitative PCR (qPCR) was done on the Stratagene
MX3000P. All cDNA samples were assayed in triplicates
except the Origene Lung Expression Panels, which were
run in duplicates for each gene probe. Mouse tumor
samples were assayed with the Mouse ACTB-VIC/MGB
probe (ABI) as an endogenous control and GPR110
probe Mm00505409_m1 (ABI). Tumor samples contain-
ing no integration sites in the GPR110 locus were used
as control tumors. Relative expression values (2
-ΔΔCt)
were calculated using normal mouse spleen cDNA.
GUSB (Hs99999908_m1, ABI) was used as an endogen-
ous control for all human samples. ABI Taqman probe
Hs00228100_m1 (spanning exons 2 and 3) was used to
detect human GPR110. The following SYBR primers
were used to detect the three GPR110 isoforms in
GPR110 positive cell lines: Isoform 1 - 5’-
CTTTCTGTCATCATTCGGCAAAAC-3’ and 5’-
TTGGTTACTGAGGCTGAATTAAGG-3’,I s o f o r m2-
5’-GAATTCATCTTCTGCTATATACTCC-3’ and 5’-
CCAACTTGGGCGACAAGAGTGAC-3’,I s o f o r m3-
5’-CAACAACCTCAGCCAGAGTGT-3’ and 5’-
ATGCCCTTCTAAGACCATTGTGT-3’, and endogen-
ous control GUSB - 5’-CACTGAAGAGTACCA-
GAAAAGTC-3’ and 5’-
TCTCTGCCGAGTGAAGATCC-3’.
Immunohistochemistry
Human tissue arrays containing formalin-fixed paraffin-
embedded tissues (Cybrdi) were processed according to
standard procedures. LS-A2021 and LS-A2019 (MBL
International), or control rabbit IgG antibodies (Invitro-
gen) were incubated with the arrays for 1 hour at room
temperature. For detection of bound antibody, the arrays
were then processed using the SuperPicture kit (Invitro-
gen) according to the manufacturer’s instructions.
Identification of provirus integration sites
The genomic locations of the proviral integrations were
determined using the splinkerette-based PCR method
[5]. This method recovers genomic DNA directly flank-
ing the 5’ LTR of the integrated provirus. Genomic
DNA was isolated from tumors using the DNeasy Tissue
kit (Qiagen) and digested using restriction enzymes
BstYI or NspI. A double-stranded splinkerette adapter
molecule [6] containing the appropriate restriction site
was ligated to the digested genomic DNA using the
Quick Ligation kit (New England Biolabs). These liga-
tion products were then digested with EcoRV to prevent
subsequent amplification of internal viral fragments.
The resulting mixture was purified using QIAquick PCR
purification kits (Qiagen), and subject to three rounds of
PCR using nested PCR primers that had homology to
the adapter DNA and to the 5’ LTR sequence of the
SL3-3 virus. After resolving the PCR products by gel
electrophoresis, the desired bands were purified using
QIAquick Gel Extraction kits (Qiagen) and subject to
standard DNA sequencing.
Results and discussion
Structure and mRNA expression of the GPR110 gene
Not only is the ligand(s) of GPR110 unknown, but also
very little is known about the putative transcripts that
direct protein synthesis. To date, all published research
on GPR110 has dealt with its sequence identification
and analysis [7-9]. Public genome databases give some
information about GPR110, and there is one publication
that analyzes potential GPR110 splice variants in silico
[9]. According to these sources, human GPR110 is
located on chromosome 6. Two mRNAs are reported
for this gene: isoform 1 (NM_153840.2), which encodes
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seven-span transmembrane region of G-protein-coupled
receptors, and isoform 2 (NM_025048.2), a truncated
version of isoform 1.
Using cDNAs from various primary prostate and lung
tumors, we searched for novel PCR products in the
extracellular domain of GPR110. A summary of GPR110
isoforms is shown in Figure 1A. Isoform 2 is identical in
sequence to isoform 1 up to an alternative splicing of
exon 6 to a unique exon 7 (exon 7a), which ends the
transcript and adds several additional amino acids. From
primer sets designed to the 5’ and 3’ UTRs of isoform 2,
we detected isoform 3, which was not spliced between
exons 6 and 7a. An in-frame stop codon at the start of
the intron between exons 6-7a causes the putative pro-
duct of isoform 3 to be a truncated form of isoform 1,
coding for only exons 1 through 6. Isoform 4, an addi-
tional isoform detected by PCR between the 5’ UTR and
exon 6 of isoform 1, splices directly from exon 1 to
exon 3. Because the deletion of exon 2 is not in frame,
the isoform 4 mRNA would encode a polypeptide of
only 34 amino acid residues; thus, this isoform was not
further examined. We detected no other isoforms apart
from these four. To test whether or not these isoforms
are actually expressed, we quantified the relative expres-
sion levels of isoforms 1, 2, and 3 by quantitative PCR
in cell lines PC-3, LNCaP, and A549. Isoform 1 was
detected in all three cell lines and was the predominant
form found. Additionally isoform 2 was detected in PC-
3 and LNCaP at lower levels than isoform 1. Isoform 3
was detected only in PC-3 (Figure 1B and data not
shown). In PC-3, the cell line expressing all three iso-
forms, isoform 1 had 10-fold-higher expression than iso-
form 2 and 100-fold-higher expression than isoform 3
(Figure 1B).
Expression of GPR110 polypeptides in cell lines
Of the three isoforms, isoform 1 must be the canonical
form, with a predicted molecular mass of about 100 kD.
Isoforms 2 and 3–truncated products of isoform 1–are
25 and 23 kD, respectively. These isoforms lack the
seven-span transmembrane domain and thus are not
likely to be membrane anchored. However, the presence
of a signal peptide suggests isoforms 2 and 3 may be
potentially secreted. Figure 1C shows the various
domains of the full-length protein. Apart from the signal
peptide, the figure depicts three protein domains: (1) an
SEA domain, (2) a GPS domain, and (3) a 7TM (seven
transmembrane domain). The SEA domain is a con-
served protein domain with an unknown function that
was first observed in Sea urchin sperm protein, Entero-
kinase, and Agrin. Self-cleavage was reported for this
domain in human MUC1 [2] and in rat Muc3 [3]. The
cleaved SEA product has been shown to reassociate
with the membrane-bound protein by noncovalent inter-
actions [10]. The predicted GPR110 SEA domain con-
tains the sequence GSIVA, ~24 kD downstream of the
N terminus, which is consistent with the reported SEA
consensus cleavage site G^SVVV. Cleavage in the GPS
domain was first shown in the GPCR latrophilin [4].
GPR110 contains the consensus GPS cleavage site
H^LT, ~63 kD downstream of the N terminus.
We constructed C-terminal HA-tagged versions of the
three isoforms to determine their expression and possi-
ble secretion (Iso1-HA, Iso2-HA, and Iso3-HA). To aid
in the detection of potential cleavage sites, we made
three additional HA-tagged versions of isoform 1
through site-directed mutagenesis: one construct with
an HA tag located N terminal to the SEA domain
(HA466), and two others with tags located between the
SEA and GPS domains (HA1036 and HA1393) (Figure
1C). To check protein expression, we transiently trans-
fected the tagged constructs of isoforms 1-3 into the cell
lines HEK 293T/17, HeLa, PC-3, and A549, and
detected the HA tag in cell lysates by western blot. As
seen in Figure 2, all three isoforms are produced (data
for A549 not shown), with the major protein bands
being identical across cell lines for each tagged isoform
(Figure 2A, lane 1). Isoform 2 transfections contain four
major bands ranging from 28 to 39 kD, while isoform 3
transfections produce three bands ranging from ~25 to
35 kD (Figure 2A), indicating various glycosylated forms
(see below). Iso1-HA (C-terminal HA tag) transfections
give two major high molecular weight bands at ~80 and
100 kD (Figure 2A, arrows). HA1393 (tagged between
the SEA and GPS, see Figure 1C) displays the same
major bands as Iso1-HA. However, HA466, which con-
tains the HA tag N-terminal to the SEA domain, only
contains the 100 kD band along with a unique pair of
bands at ~30 kD (Figure 2A, arrows). The banding pat-
tern of the isoform 1 tagged proteins suggests that the
100 kD band represents a full-length version of GPR110
while the 80 kD (of HA1393 and Iso1-HA) and 30 kD
bands (of HA466) may result from a potential SEA clea-
vage (Figure 2A).
Because GPR110 contains 19 predicted N-linked gly-
cosylation sites, the bands running at 100 and 80 kD fall
short of the expected size. However, the banding pattern
of the tagged GPR110 proteins does not indicate the
presence of another cleavage site. To estimate the sizes
of the non-glycosylated protein, cell lysates from trans-
fected HEK cells were treated with the glycosidase
PNGaseF. This treatment reduced the four bands of iso-
form 2 to a single band of the expected molecular
weight of 26 kD (molecular weight plus tag), and iso-
form 3 to ~25 kD (MW plus tag) (Figure 2B). Thus,
both isoforms 2 and 3 are produced at the expected
molecular weight in multiple cell lines and are present
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Page 4 of 14Figure 1 GPR110 transcripts and isoform 1 polypeptide. (A) Schematic of the four human GPR110 transcript isoforms, as gleaned from the
UCSC genome web browser (chromosome 6, March 2006 version of the hg18 assembly). Isoform 1 encodes the full-length protein containing
14 exons. Isoform 2 contains an alternative splicing of exon 6 to exon 7a. Locations of in frame stop codons are shown for isoforms 3 and 4. (B)
Relative expression of GPR110 isoforms 1-3 in human cell line PC-3. Transcript levels of isoforms 1 through 3 were measured by SYBR qPCR.
Expression values were calculated relative to isoform 3 expression. Although qPCR analysis of the three GPR110 isoforms was done on the three
prostate cells lines mentioned, as well as the three lung cell lines used in this study (A549, H460 and H23), we detected Isoform 2 only in PC-3
and LNCaP; and Isoform 3 only in PC-3. Thus, the data for all 3 isoforms are shown only for PC-3. (C) Schematic representation of the primary
polypeptide structure of GPR110. SEA, SEA domain; GSIVA, amino acid sequence with potential for cleavage; GPS, GPS domain, with predicted
cleavage at amino acid sequence HLT; 7TM, seven-span transmembrane domain. Blue triangles, predicted cleavage sites in the SEA and GPS
domains; red triangles, locations of HA tags in isoform 1. Scale indicates peptide size, in kiloDaltons (kD).
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ted isoform 1 reduces the two major bands of 80 and
100 kD to 60 and 75 kD, respectively (Figure 2C,
arrows). The pair of bands in HA466 at 30 kD also
reduces to a single band at ~25 kD, which agrees with
the size of an SEA cleavage product (Figure 2C, arrow).
Expression of isoforms on the cell surface
As a member of the GPCR family, GPR110 isoform 1 is
expected to be present at the cell surface, but because
isoforms 2 and 3 both lack the seven transmembrane
domain, they may not be. To determine whether the
isoforms reach the cell surface, we transiently trans-
fected HEK cells with constructs encoding isoforms 1, 2
and 3. We then labeled all cell surface proteins with bio-
tin using a crosslinking reagent, lysed the cells, and pur-
ified the proteins using avidin-linked agarose beads.
Fractions from the cell surface isolation procedure,
lysate (L in Figure 3A), unbound (U), and bound (B),
were analyzed by western blot for GAPDH, a known
cytosolic protein (36 kD), integrin b1, a known surface
protein (130 kD), and the HA tag. Proteins detected in
Figure 2 Production of three GPR110 isoforms in human cell lines. (A) HA-tagged isoforms 1-3 were transiently expressed in HEK (lane1),
HeLa (lane 2), and prostate line PC-3 (lane 3). Protein production detected by immunoblot with HA.11 antibody, which is specific to the HA tag;
protein ladder molecular weights at the far left, in kD. Arrows point to the two major 80 and 100 kD molecular weight bands of isoform 1; and
to a 30 kD band, representing a putative cleaved product. (B) isoforms 2 and 3, and (C) the four HA tagged isoform 1 proteins in HEK lysates (L)
treated with (+) or without (-) glycosidase PNGaseF. Cterm, C-terminal HA-tagged isoform 1. Arrows point to the two major 60 and 75 kD bands
after glycosidase treatment; and to a putative SEA cleavage product (in dotted box).
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considered present on the cell surface. As can be seen
in Figure 3A on the western blot developed with anti-
GAPDH (first blot, arrow), GAPDH does not appear in
the bound fractions in any of the transfections, indicat-
ing it is not on the surface, while our positive cell sur-
face control, integrin b1 (second blot, arrow), appears in
the bound fraction as expected.
For isoform 1, we assayed lysates of cells transfected
with constructs HA466, HA1393, and Iso1, an untagged
version of isoform 1 for which no bands are expected
(Figure 3A third blot). Due to the presence of the
seven-transmembrane region, Isoform 1 is likely to be
on the cell surface, as indicated by the 100 kD band
(arrow). The 80 kD band of HA1393 is also present,
though as a smeared band. When we treated the surface
protein fractions with PNGaseF, the 100 and 80 kD
bands shifted to ~75 and 60 kD (Figure 3B, arrows), as
seen before in the lysates that were not biotinylated. In
addition, there is a faint band at 25 kD in the HA466
transfectant (lower arrow), which indicates that the
cleaved SEA fragment may reach the cell surface in
small quantities. Unexpectedly, the C-terminal HA
tagged isoforms 2 and 3 are also detected in the cell
surface fraction (Figure 4, third blot), though at levels
lower than for isoform 1. The presence of isoforms 2
and 3 may be due to temporal association from passage
through the cell membrane en route to being secreted,
or to interactions with other proteins on the cell surface,
including isoform 1.
Protein secretion
As shown in the previous sections, all three GPR110 iso-
forms can be produced within human cell lines. These
isoforms also reach the cell surface. To address whether
any of these isoforms are secreted, we recovered media
from HEK cells transfected with the GPR110 isoforms,
and immunoprecipitated (IP) using an anti-HA antibody
Figure 3 Isoform 1 is on the cell surface. Western blots of fractions of surface biotinylated HEK cells transfected with HA tagged GPR110
isoform 1 constructs (HA466 and HA1393), or with no tag (Iso1). (A) Developed with antibody to GAPDH (first blot), to integrin (second blot), or
HA.11 antibody (third blot). L, lysate; U, unbound, and B, bound cell surface fraction. GAPDH is a cytosolic protein (arrow on the first blot); and
integrin b1 is a surface protein (arrow on the second blot). Arrow on the third blot, 100 kD band of isoform 1. (B) Treatment of tagged GPR110
isoform 1 surface fractions with (+) or without (-) PNGaseF; developed with HA.11 antibody. Arrows point to the 60 and 75 kD bands, a result of
the PNGaseF treatment; and to a 25 kD band, of the putative SEA fragment.
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tion led to a 40-fold enrichment of GPR110 over the
concentration in the culture media. Cell lysates (L) and
the IP fraction of the media (M) were assayed by wes-
tern blot for the GPR110 isoforms using the HA.11 anti-
body (Figure 5). In the mock-transfected control, there
are no protein bands in the cell lysate lanes, and only
bands representing the heavy and light chains of the
HA.11 antibody are present in the media fraction (Fig-
ure 5A, first blot). All isoform encoding constructs pro-
duce their respective polypeptides, as seen in the cell
lysates. However, only isoform 2 is present in the media
fraction, (Figure 5A, arrow on second blot). Secreted
isoform 2 runs as smeared bands slightly higher in
molecular weight than the lysate bands (Figure 5A,
arrow). When treated with PNGaseF, both lysate and
media fractions collapsed to a single band at ~26 kD,
confirming that all these bands represent isoform 2
(note that in the media fraction this band merges with
the light chain of the precipitating antibody) (Figure 5B,
arrow). These assays demonstrate that isoform 2, but
not isoform 1 or 3, is secreted.
Figure 4 Isoforms 2 and 3 are on the cell surface. Western blots of fractions of surface biotinylated HEK cells transfected with C-terminal HA
tagged isoforms 2 (Iso2) and 3 (Iso3), developed with antibody to GAPDH (first blot; arrow points to GAPDH), to integrin b1 (second blot; arrow
points to integrin b1), and HA.11 antibody (third blot), respectively. pcDNA3.1, empty vector; L, lysate; U, unbound, and B, bound cell surface
fraction.
Figure 5 Isoform 2 is secreted. Western blots of immunoprecipitates of cell culture media from GPR110 transfections; developed with antibody
HA.11. (A) L, lysate; M, immunoprecipitate from media. HA466 and HA1393, two versions of HA-tagged isoform 1; Iso2-HA and Iso3-HA, HA-
tagged isoform 2 and 3, respectively. Arrow points to the secreted form of isoform 2. (B) PNGaseF treatment of lysate and media of cells
transfected with Iso2-HA. Arrow points to the deglycosylated isoform 2.
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Having identified isoforms that are encoded by the
GPR110 gene, we determined the expression of GPR110
in 15 normal human tissues by quantitative PCR. For
this we used a Taqman probe spanning exons 2 and 3
(ExJ2-3) of GPR110, which measures both isoforms 1
and 2; and GUSB, a moderately expressed gene, as an
endogenous control gene. The relative expression of
GPR110, as compared to the median gene expression of
~200 selected genes within each tissue, was low in most
tissues, except in kidney and prostate (Figure 6A).
Because the tissue panel included prostates from older
men (three donors, 78-79 years of age) who may be
afflicted by benign prostate hyperplasia or undiagnosed
prostate cancer, we also assayed two samples of prostate
tissue from donors under 30 years of age. In these sam-
ples, GPR110 expression was at least 6-fold lower than
in the prostate from the original panel (Figure 6B), indi-
cating that GPR110 expression in healthy prostate typi-
cally may be low.
GPR110 is a proto-oncogene
In a large retroviral insertion screen in mice [11-14], we
have identified Gpr110 as an oncogene. In this screen,
proviral enhancers or promoters activate proto-onco-
genes to become oncogenes, which cause tumors to
grow. The relevant oncogene can be determined by the
position of the provirus. Figure 7 shows the relative
Figure 6 GPR110 is mainly expressed in the kidney. (A) Quantitative PCR measurements of expression across a human normal tissue panel,
relative to the median gene expression of ~200 selected genes within each tissue. (B) Prostate samples from two young donors (24 and 27 yr)
compared to the panel sample of RNA from the prostates of three 78-79 yr old men. The error bars represent technical replicates.
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Page 9 of 14expression of Gpr110 in two mouse T lymphomas with
overexpression of Gpr110 (first two bars to the left)
compared to 14 other tumors with no insertions into
this locus (tumor controls) and normal mouse spleen.
Gpr110 expression in tumor 754S was ~60-fold higher
than in normal mouse spleen (Figure 7). In this tumor,
the provirus had integrated into the first intron of the
Gpr110 gene, presumably driving the tumor. Tumor
3271S had over 1000-fold higher expression. However,
the cause of Gpr110 overexpression in 3271S is
unknown, since we did not recover a tag at the locus.
This may have been due to technical failure, or overex-
pression of Gpr110 may be caused by another mutation
within members of the Gpr110 pathway. Our result that
Gpr110 can be an oncogene in mouse leukemia has
been confirmed by four additional retroviral integration
sites identified at the Gpr110 locus on mouse chromo-
some 17: one integration site 5’ to the gene, published
in the RTCGD [15], and most recently three integra-
tions (two into intron 1, as we have found, and one into
intron 14 of the 15 introns of the gene) detected by
Uren, et al. [16]. Considering this number of integration
sites, it is very likely that Gpr110 is a protooncogene in
the mouse [15].
GPR110 overexpression in human lung cancer
Having identified GPR110 as an oncogene, we screened
v a r i o u st u m o rs a m p l e sf o ri t so v e r e x p r e s s i o n .W e
assayed three human lung cancer cell lines (A549, H460,
and H23) by qPCR for GPR110 using the ExJ2-3 Taq-
man probe, and EGFR, a gene frequently mutated or
amplified in lung cancer. All three lines express EGFR
at levels equal to GUSB (data not shown). Although
GPR110 is only moderately expressed in A549 and
weakly, if at all, expressed in H460 and H23 (Figure
8A), we decided to assay primary lung tumors. In one
set of lung adenocarcinoma RNA samples, four of 15
tumors contained 8-fold to over 100-fold higher
GPR110 RNA levels than normal lung samples (Figure
8B). After this initial tumor screening by qPCR (Figure
8B), we predicted overexpression of GPR110 in adeno-
carcinoma samples, and in the following qPCR experi-
ments of another set of tumor samples (Figure 8C), 4
out of 11 (36.4%, exact 95% confidence limits 15.2 -
65.1%) adenocarcinomas showed more than five-fold
relative overexpression, whereas none of the eight (0%,
0.3 - 33.6%) normal lungs did, at an average relative
expression level of 1.0 ± 1.5. In the other samples, of
squamous lung cancer, the overexpression of GPR110
was less pronounced (Figure 8C).
To confirm our data obtained with qPCR, we per-
formed immunohistochemistry on primary lung cancer
tissue cores. Currently there are no commercially avail-
able monoclonal antibodies for GPR110. The polyclo-
nal peptide antibodies LS-A2021 and LS-A2019 work
well in staining on formalin-fixed paraffin-embedded
Figure 7 Gpr110 is an oncogene. Quantitative PCR measurements of Gpr110 expression in mouse T lymphomas generated by murine
leukemia virus. Y-axis, relative expression on a logarithmic scale; x-axis, various T lymphomas. Tumors 754S and 3271S show overexpression of
Gpr110. Tumor controls are RNAs from mouse tumors with no retroviral tags recovered from the Gpr110 locus. ‘Normal’ bar represents RNA from
normal mouse spleen.
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Page 10 of 14Figure 8 GPR110 mRNA overexpression in human lung cancer. GPR110 expression, as measured by qPCR with an exon junction 2-3 Taqman
probe, and GUSB, glucuronidase beta, as a standard; in (A) lung cell lines A549, H23 and H460; y-axis, fluorescence; x-axis, number of cycles of
amplification needed to reach a set value; in one set of (B) lung adenocarcinoma tumor samples and normal lung samples (Asterand); and in
another set of (C) lung tumor and normal lung samples (Origene). The samples in (B) and (C) are separate cohorts, with (B) all representing
adenocarcinomas. Tumors in (C) were sorted according to tumor type. The category of “other” includes adenosquamous, large cell, non-small,
and sarcomatoid carcinomas. Numbers on the x-axis in (C) indicate well location on the Origene Lung TissueScan plate. Y-axis in (B) and (C)
displays relative expression (2
-ΔΔCt) normalized to average expression in the normal lung samples.
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Page 11 of 14tissue sections (Figure 9); LS-A2021 was generated
from a peptide near amino acid 175 (originating from
exons 5 and 6), while LS-A2019 was produced from a
peptide near amino acid 50 (exon 3). Of the three pep-
tides spanning amino acids 162-199 (Figure 9A) that
were co-incubated with LS-A2021 to lung cancer tissue
arrays, only peptide 2 resulted in decreased signal in
cores testing positive for GPR110 (Figure 9B), indicat-
ing that LS-A2021 binds to a sequence contained
within this peptide. The two GPR110 antibodies pro-
duced strong IHC staining in lung adenocarcinoma tis-
sue sections (Figure 9C). Staining in normal lung
tissue was low in type II pneumocytes, the presumed
precursor cells of lung adenocarcinomas (Figure 9C).
LS-A2021 and LS-A2019 stained respectively over 70%
(20/27) and 30% (9/27) of lung tissue samples.
Although there were tumors that stained with only one
antibody (types 1 and 3), most cores stained by LS-
A2019 were also stained by LS-A2021 (Figure 9, type
2). Here we think that the two antibodies may differ-
entiate between GPR110 isoforms.
GPR110 overexpression in prostate cancer
Because the normal tissue screen indicated that GPR110
may be elevated in prostate tissue with increased age
and thus hyperplasia, we also measured GPR110 expres-
sion in three commonly studied prostate lines, PC-3,
LNCaP, and DU145. In PC-3, a prostate adenocarci-
noma cell line, GPR110 expression was high (Figure
10A); LNCaP tested weakly positive for GPR110, while
Figure 9 GPR110 protein overexpression in paraffin sections of lung cancer tissue. Immunohistochemistry on human lung cancer tissue
arrays with consecutive sections, including normal controls, with antibodies LS-A2021 and LS-A2019. (A) Three peptides spanning amino acids
162-199 of GPR110. (B) Binding of LS-A2021 antibody to lung samples was competed with the three peptides. Peptide 2 decreased staining in
GPR110-positive tissue samples, whereas lack of peptide, and peptides 1 and 3 did not. (C) Examples of cores staining with LS-A2021 only (type
1), with both antibodies (type 2), and with LS-A2019 only (type 3); there was no staining with IgG controls (not shown).
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Page 12 of 14DU145 was negative (Figure 10A). In these lines, we also
measured expression of PSA, a diagnostic marker for
prostate cancer. While LNCaP tested positive for PSA
expression at a level comparable to GPR110 expression
in PC-3, both PC-3 and DU145 tested PSA negative
(Figure 10A).
As before with the lung cancer tissue cores, we also
performed immunohistochemistry on prostate tissues.
On these, we hypothesized that GPR110 expression may
enable us to differentiate between benign prostate
hyperplasia (BPH) and potential incipient malignancy.
On BPH cores, 94% (33/35) were positive for PSA (Fig-
ure 10B, right panels, cores 1 and 2 shown), and 26%
(9/35) were positive with antibody LS-A2021 (Figure
10B, left panels). In these tissues, however, only the few
cells that are PSA negative are positive for the epitope
stained by LS-A2021 (Figure 10B, arrows); most of the
tissue core is negative for LS-A2021 staining. Because
Figure 10 GPR110 overexpression in prostate benign hyperplasia and cancer. (A) GPR110 expression, in prostate cancer lines PC-3, LNCaP,
and DU145, as measured by qPCR with an exon junction 2-3 Taqman probe; and GUSB, glucuronidase beta, as a standard. (B)
Immunohistochemistry on two benign prostate hyperplasia cores, BPH-1 (upper) and BPH-2 (lower). Left, stained with antibody LS-A2021; right,
consecutive sections of the same cores, stained with antibody to PSA. No staining was observed with secondary and irrelevant primary antibody
(not shown). Note that the LS-A2021 positive cells are PSA negative, and vice versa (arrows). (C) Consecutive paraffin sections of two different
prostate adenocarcinoma cores (1 and 2, left and right, respectively), stained with LS-A2021 antibody (upper two pictures) or LS-A2019 antibody
(lower two pictures). Note that staining by the one antibody excludes staining by the other antibody.
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Page 13 of 14antibody to this epitope stains prostate adenocarcinoma
(see below), we interpret this to possibly mean that
among the hyperplastic non-cancerous epithelial cells,
adenocarcinoma cells slowly begin to develop. Here it is
not clear whether the carcinoma cells are derived from
the BPH cells, although it is intriguing to note that
expression of the epitopes of GPR110 and PSA are
mutually exclusive. In prostate adenocarcinomas, LS-
A2021 stained over 50% (17/29) of tissue cores while
LS-A2019 stained over ~30% (10/29) (Figure 10C). Most
of the cores with LS-A2019 staining also tested positive
with LS-A2021, but the two antibodies displayed differ-
ential staining in these overlapping cores. This differen-
tial staining may be due to various splice forms of
GPR110 or to different post-transcriptional processing
of GPR110 in these prostate cancers.
Conclusion
In a large retroviral mutagenesis screen, we identified
Gpr110 as an oncogene. As an orphan G protein-
coupled receptor, this protein has not been subject to
experimental study. We identified three isoforms of
GPR110 at the protein level by their production in mul-
tiple human cell lines. Isoform 1 is cleaved within the
SEA domain and isoform 2 is secreted into the culture
medium. However, all isoforms are glycosylated, and all
are present on the cell surface. At the transcript level,
GPR110 is overexpressed in some lung tumors as well
as highly expressed in a commonly used prostate cancer
cell line. In lung and prostate tumor tissue cores,
GPR110 protein is overexpressed, and it may differenti-
ate between benign prostate hyperplasia and prostate
carcinoma. This work supports GPR110 as a potential
therapeutic candidate and disease marker for both lung
and prostate cancer.
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